Why a Hedge Fund Sold Most of Its Genius Sports Stake Despite Best Quarterly Performance in Years

Cooper Creek Partners sold nearly 7.5 million shares of Genius Sports (estimated $74.1M) in Q3, cutting its stake from roughly 3% of 13F AUM to 0.7%, leaving 1.7 million shares valued at $21.5M at quarter-end. Genius reported 38% revenue growth to $166.3M for the quarter, raised full-year guidance to $655M in 2025 revenue and $136M adjusted EBITDA, and has TTM revenue of $604.5M with a market cap of $2.4B (price $10.07). The trade highlights a divergence between improving operational metrics and institutional positioning, suggesting sentiment-driven volatility despite strengthening fundamentals.

Analysis

Market structure: Cooper Creek’s ~7.5M-share Q3 sale (~$74M) is a liquidity event, not a fundamental verdict; it temporarily increases available float and likely amplified short-term selling pressure, benefiting intra-day liquidity providers, short sellers and buy-the-dip retail/institutional buyers. Genius’s pricing power for league/data contracts remains the primary driver of long-term value — one big holder trimming does little to change durable contract economics or media distribution fees.

Risk assessment: Tail risks include (1) adverse regulatory moves on sports-data licensing or US state betting rules, (2) loss/renegotiation of one or more large league contracts, and (3) a major data-integrity/tech breach; each could remove >20-30% of forecast EBITDA in stress scenarios. Short-term (days–weeks) expect volatility and potential 10–20% moves on flow; medium-term (quarters) outcomes hinge on hitting FY25 guidance ($655M revenue, $136M adj EBITDA); long-term (years) depends on network effects, exclusivity and margin expansion.

Trade implications: Favor a constructive overweight on GENI vs a generic small-cap tech basket while hedging execution risk: size initial exposure 2–3% of NAV, target +40–60% upside to $14–$16 in 6–12 months if guidance is met, stop-loss -25% (~$7.50). Use options to express convexity: buy Jan 2026 LEAP calls (synthetic example buy 1x GENI Jan26 $12 call / sell Jan26 $22 call) sized to 1% NAV, or buy 3–6 month protective puts if entering at current levels.

Contrarian angles: The market is underestimating the stickiness of league contracts and recurring data revenues — Cooper Creek’s trim looks tactical reallocation given other large stakes in non-tech names. If GENI trades below $8 on >2x ADV selling, treat as tactical accumulation (add to 4% NAV max); conversely, if it rallies above $16 without clear new wins, pare back to lock gains.

Key Decisions for Investors

• Establish a 2–3% NAV long position in GENI (ticker GENI) over the next 2–6 weeks, target exit price $14–$16 within 6–12 months if company hits FY25 guidance; initial stop-loss at -25% (~$7.50).
• Buy a capped-leverage options spread to express upside with controlled cost: buy Jan 2026 GENI $12 call and sell Jan 2026 $22 call sized to 1% NAV (or nearest liquid strikes) to target asymmetric upside while limiting premium outlay.
• If GENI falls below $8 on >2x average daily volume, add to position up to 4% NAV and simultaneously buy 3–6 month protective puts (strike $7.50) on half of the added allotment to protect against further flow-driven downside.
• Implement a paired hedge: long GENI (2–3% NAV) v. short DraftKings (DKNG) at 0.4x notional for 3–6 months to reduce exposure to betting operator cyclicality; trim hedge if GENI reports material contract renewals or if DKNG reports positive margin expansion.